shutterstock_726176974_albinaglisic
albinaglisic / Shutterstock.com
1 April 2019Big Pharma

FTC rules Impax received illegal payments to block pain reliever generic

Pharmaceutical company Impax Laboratories engaged in illegal pay-for-delay settlements to stop a generic version of one of Endo Pharmaceutical's medications from entering the market, the US Federal Trade Commission has ruled.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
30 April 2018   The Federal Trade Commission is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.

More on this story

Americas
30 April 2018   The Federal Trade Commission is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.

More on this story

Americas
30 April 2018   The Federal Trade Commission is requiring Impax to divest rights and assets for ten products, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition would be anti-competitive.